Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin plus rifaximin to prevent ACLF in decompensated cirrhosis
2018-001698-25Phase 3Completed
- Sponsor
- August Pi i Sunyer Biomedical Research Institute
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis comparing Simvastatin + rifaximin with Placebo (2 arms). Primary endpoint: Time to first incidence of acute-on-chronic liver failure (ACLF). Started Jul 2018; status: completed.
02
Drugs
simvastatinrifaximin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2018-001698-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001698-25.